Literature DB >> 17345122

Peripheral arterial occlusive disease: magnetic resonance imaging and the role of aggressive medical management.

Alan B Lumsden1, Terry W Rice, Changyi Chen, Wei Zhou, Peter H Lin, Paul Bray, Joel Morrisett, Vijay Nambi, Christie Ballantyne.   

Abstract

Atherosclerosis accounts for most peripheral arterial occlusive disease (PAD). Although many of the risk factors for atherosclerotic coronary artery disease (CAD) such as hyperlipidemia have been identified as risk factors for peripheral arterial disease, strong evidence is lacking that risk factor modification is effective in halting progression or improving outcomes. A better understanding is needed regarding the clinical and pathophysiologic responses to risk factor modification. This review describes current advances in the medical management for PAD including lipid modification antiplatelet therapy, angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, exercise, and endovascular intervention. In addition, we discuss our active ELIMIT Trial (Effect of Lipid Modification on Peripheral Arterial Disease after Endovascular Intervention). We test the hypothesis that an aggressive regimen of serum lipid modification will inhibit the progression of atherosclerosis in femoral arteries and reduce the incidence of restenosis of femoral arteries following endovascular stenting by decreasing thrombosis and inflammation. This study will provide a novel strategy for retarding or preventing progression of atherosclerosis and re-stenosis of peripheral arterial disease following arterial revascularization procedures. Importantly, our magnetic resonance imaging studies will provide quantitative data on the vascular lesions in PAD. These studies will advance our understanding of the molecular mechanisms of inflammation and thrombosis associated with aggressive lipid modification.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17345122     DOI: 10.1007/s00268-006-0732-y

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  52 in total

1.  Percutaneous transluminal angioplasty versus operation for peripheral arteriosclerosis. Report of a prospective randomized trial in a selected group of patients.

Authors:  S E Wilson; G L Wolf; A P Cross
Journal:  J Vasc Surg       Date:  1989-01       Impact factor: 4.268

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

Review 3.  An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program.

Authors:  B J Ansell; K E Watson; A M Fogelman
Journal:  JAMA       Date:  1999-12-01       Impact factor: 56.272

4.  Mortality over a period of 10 years in patients with peripheral arterial disease.

Authors:  M H Criqui; R D Langer; A Fronek; H S Feigelson; M R Klauber; T J McCann; D Browner
Journal:  N Engl J Med       Date:  1992-02-06       Impact factor: 91.245

5.  In-plane vascular imaging: pulse sequence design and strategy.

Authors:  G W Lenz; E M Haacke; T J Masaryk; G Laub
Journal:  Radiology       Date:  1988-03       Impact factor: 11.105

6.  Atherosclerotic risk factor control in patients with peripheral arterial disease.

Authors:  Thomas F Rehring; Brian G Sandhoff; Ryan S Stolcpart; John A Merenich; H Whitton Hollis
Journal:  J Vasc Surg       Date:  2005-05       Impact factor: 4.268

7.  Peripheral arterial disease detection, awareness, and treatment in primary care.

Authors:  A T Hirsch; M H Criqui; D Treat-Jacobson; J G Regensteiner; M A Creager; J W Olin; S H Krook; D B Hunninghake; A J Comerota; M E Walsh; M M McDermott; W R Hiatt
Journal:  JAMA       Date:  2001-09-19       Impact factor: 56.272

Review 8.  Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.

Authors:  Steven E Nissen
Journal:  Am J Cardiol       Date:  2005-09-05       Impact factor: 2.778

Review 9.  Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.

Authors:  Y Liu; Y Shakur; M Yoshitake; J Kambayashi Ji
Journal:  Cardiovasc Drug Rev       Date:  2001

10.  Platelet cytosolic Ca2+ and membrane dynamics in patients with primary hypercholesterolemia. Effects of pravastatin.

Authors:  K H Le Quan Sang; J Levenson; J L Megnien; A Simon; M A Devynck
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-06       Impact factor: 8.311

View more
  12 in total

1.  Magnetic resonance imaging-based computational modelling of blood flow and nanomedicine deposition in patients with peripheral arterial disease.

Authors:  Shaolie S Hossain; Yongjie Zhang; Xiaoyi Fu; Gerd Brunner; Jaykrishna Singh; Thomas J R Hughes; Dipan Shah; Paolo Decuzzi
Journal:  J R Soc Interface       Date:  2015-05-06       Impact factor: 4.118

2.  Calf muscle perfusion as measured with magnetic resonance imaging to assess peripheral arterial disease.

Authors:  Gerd Brunner; Jean Bismuth; Vijay Nambi; Christie M Ballantyne; Addison A Taylor; Alan B Lumsden; Joel D Morrisett; Dipan J Shah
Journal:  Med Biol Eng Comput       Date:  2016-02-23       Impact factor: 2.602

3.  Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients.

Authors:  Justin Saunders; Vijay Nambi; Kay T Kimball; Salim S Virani; Joel D Morrisett; Alan B Lumsden; Christie M Ballantyne; Jing-Fei Dong
Journal:  J Vasc Surg       Date:  2011-01-12       Impact factor: 4.268

4.  Discovery of a pyrazole derivative promoting angiogenesis through modulating reactive oxygen species and interferon-inducible protein 10 levels.

Authors:  Maohua Wang; Jingyong Zhang; Xuejun Wu; Xing Jin; Baoxiang Zhao; Lu Zhang; Hai Yuan; Hua Zhou; Binbin Gao; Wei Lv; Xiangqian Kong; Junying Miao
Journal:  Mol Biol Rep       Date:  2010-09-15       Impact factor: 2.316

5.  The association of lesion eccentricity with plaque morphology and components in the superficial femoral artery: a high-spatial-resolution, multi-contrast weighted CMR study.

Authors:  Feiyu Li; Mary McGrae McDermott; Debiao Li; Timothy J Carroll; Daniel S Hippe; Christopher M Kramer; Zhaoyang Fan; Xihai Zhao; Thomas S Hatsukami; Baocheng Chu; Jinnan Wang; Chun Yuan
Journal:  J Cardiovasc Magn Reson       Date:  2010-07-01       Impact factor: 5.364

6.  Magnetic Resonance Venous Volume Measurements in Peripheral Artery Disease (from ELIMIT).

Authors:  Hassan Kamran; Vijay Nambi; Smita Negi; Eric Y Yang; Changyi Chen; Salim S Virani; Panos Kougias; Alan B Lumsden; Joel D Morrisett; Christie M Ballantyne; Gerd Brunner
Journal:  Am J Cardiol       Date:  2016-08-13       Impact factor: 2.778

7.  Differences in responses of platelets to fluid shear stress in patients with peripheral artery disease (PAD) and coronary artery disease (CAD).

Authors:  Vijay Nambi; Kay T Kimball; Paul F Bray; Angela L Bergeron; Shawna L Johnson; Joel D Morrisett; Changyi Chen; Peter H Lin; Alan B Lumsden; Christie M Ballantyne; Jing-Fei Dong
Journal:  Platelets       Date:  2009-05       Impact factor: 3.862

8.  The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT).

Authors:  Gerd Brunner; Eric Y Yang; Anirudh Kumar; Wensheng Sun; Salim S Virani; Smita I Negi; Tyler Murray; Peter H Lin; Ron C Hoogeveen; Changyi Chen; Jing-Fei Dong; Panagiotis Kougias; Addison Taylor; Alan B Lumsden; Vijay Nambi; Christie M Ballantyne; Joel D Morrisett
Journal:  Atherosclerosis       Date:  2013-10-16       Impact factor: 5.162

9.  Patient-Specific Flow Descriptors and Normalized wall index in Peripheral Artery Disease: a Preliminary Study.

Authors:  Jaykrishna Singh; Gerd Brunner; Joel D Morrisett; Christie M Ballantyne; Alan B Lumsden; Dipan J Shah; Paolo Decuzzi
Journal:  Comput Methods Biomech Biomed Eng Imaging Vis       Date:  2016-10-12

Review 10.  Perioperative statin therapy for improving outcomes during and after noncardiac vascular surgery.

Authors:  Robert D Sanders; Amanda Nicholson; Sharon R Lewis; Andrew F Smith; Phil Alderson
Journal:  Cochrane Database Syst Rev       Date:  2013-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.